Researchers used mice with nine different genetic backgrounds to identify factors influencing eye aging, paving the way for eye-based diagnostics for neurodegenerative diseases.

Vision changes are an inevitable part of aging, but why are some more susceptible to age-related eye diseases and why do some individuals experience more severe decline than others?

D Molecular Therapeutics is undervalued, with its lead candidate 4D-150 showing potential. Click here to find out why I rate ...

So far, five biosimilars that reference Eylea 2 mg have been approved by the FDA. Alvotech/Teva expect to regulatory approval ...

Cataracts occur when the lens of the eye becomes cloudy and affects the retina's ability to properly interpret and transmit signals of light to the part of the brain that ...

The U.S. Food and Drug Administration (FDA) has approved for review a Biologics License Application (BLA) for AVT06, Alvotech ...

In addition to AVT06, which is a biosimilar candidate for Eylea ® (aflibercept) 2 mg, Alvotech is currently also developing AVT29, a biosimilar candidate for Eylea ® HD (aflibercept) 8 mg. Teva also ...

AI has demonstrated remarkable proficiency in diagnosing various eye diseases, including diabetic retinopathy, glaucoma, and ...

Age-related macular degeneration (AMD) is a progressive eye condition that primarily affects people over the age of 50. AMD is a leading cause of vision loss in people over 50.

Clearside Biomedical, Inc. (NASDAQ:CLSD), currently valued at $81.15 million, is a biotechnology company focused on developing innovative therapies for blinding eye diseases using its proprietary SCS ...

Cataracts, dry eyes, glaucoma and other eye problems become more common with age. But these can be treated — and sometimes ...